Translational Oncology
Leading citation impact metric from Clarivate Journal Citation Reports
41 papers with at least that number of citations each
State Council for Professorship (HĐGSNN) Scoring
Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)
HĐGSNN Score History
By article publication year| Year | Max Score | Evaluation Details | Source |
|---|---|---|---|
| 2026 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 4.9) | 🔵 Computed |
| 2025 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 4.1) | 🔵 Computed |
| 2024 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 4.5) | 🔵 Computed |
| 2023 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 5) | 🔵 Computed |
| 2022 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 4.803) | 🔵 Computed |
| 2021 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 4.243) | 🔵 Computed |
| 2020 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.558) | 🔵 Computed |
| 2019 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.138) | 🔵 Computed |
| 2018 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.071) | 🔵 Computed |
Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.
Aims & Scope
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.
SCImago & Scopus Journal Intelligence
Not indexed in SCImago / Scopus databaseThis journal is currently not indexed in Scopus or is an academic publication indexed exclusively in Web of Science (WoS).
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
| Category | Index | Rank | Quartile |
|---|---|---|---|
ONCOLOGY | JCRSCIE | 89/333 | Q2 |
ONCOLOGY | JCISCIE | 88/333 | Q2 |
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
| Year | Impact Factor | Articles / Year | Total Citations |
|---|---|---|---|
| 2026 | — | 363 | 129 |
| 2025 | 4.1 | 378 | 1,200 |
| 2024 | 4.5 | 396 | 3,417 |
| 2023 | 5 | 241 | 3,539 |
| 2022 | 4.803 | 272 | 4,830 |
| 2021 | 4.243 | 321 | 9,830 |
| 2020 | 3.558 | 277 | 8,656 |
| 2019 | 3.138 | 164 | 4,915 |
| 2018 | 3.071 | 196 | 6,647 |
| 2017 | — | 127 | 4,280 |
| 2016 | — | 93 | 3,620 |
| 2015 | — | 68 | 2,161 |
Journal Metrics & Citation Visualizations
Impact Factor Trend (2018–2024)
Clarivate IF trend for Translational Oncology
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics